Francisco, since 1992. He has also served on the boards of numerous private companies and several non-profit organizations and has been an advisor to a wide range of organizations in the U.S. and around the world. Dr. Moos holds an A.B. from Harvard University and a Ph.D. in Chemistry from the University of California Berkeley.
Dr. Moos was selected to serve as a member of the Board in part due to his extensive leadership skills and operational expertise, as well as his expertise in the chemical sciences, which is particularly relevant to our business as we are a company focused on small molecules.
Raul R. Rodriguez, age 61, was appointed president and chief executive officer and a member of the Board of Directors in November 2014. Before being named CEO, he served as our president and chief operating officer since May 2010. He joined us as vice president, business development in April 2000, became our senior vice president, business development and commercial operations in December 2002 and became our executive vice president and chief operating officer in June 2004. From 1997 to March 2000, he served as senior vice president, business development and operations for Ontogeny, Inc. (now Curis), a biotechnology company. From 1994 to 1997, he served as the executive director, business development and market planning for Scios, Inc. (now Johnson & Johnson), a pharmaceutical company. From 1989 to 1994, Mr. Rodriguez held various positions at G.D. Searle & Company (now Pfizer), a pharmaceutical company. In these companies, Mr. Rodriguez held positions of increasing responsibility in the areas of business development and planning. After earning his bachelor’s degree from Harvard College, Mr. Rodriguez went on to earn his Master of Public Health at the University of Illinois and subsequently received his M.B.A. at the Stanford Graduate School of Business.
Mr. Rodriguez was selected to serve as a member of the Board in part due to his extensive leadership skills and operational expertise, including his operational experience and deep understanding of our business as our President and Chief Executive Officer.
DIRECTORS CONTINUING IN OFFICE UNTIL THE 2024 ANNUAL MEETING OF STOCKHOLDERS
Gregg A. Lapointe, CPA, MBA, age 63, joined us as director in November 2017. Mr. Lapointe is currently the chief executive officer and co-founder of Cerium Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing medicines for patients with rare diseases. Mr. Lapointe offers Rigel’s board nearly three decades of commercial and financial experience bringing products to market in the areas of medical devices and rare diseases. He previously served in varying roles for Sigma-Tau Pharmaceuticals, Inc. (“Sigma-Tau”), a private biopharmaceutical company, starting in 2001, including chief financial officer from 2001 to 2002, chief operating officer from 2003 to 2007, and chief executive officer from 2008 to 2012. Mr. Lapointe led the effort to transform Sigma-Tau from a small specialty dialysis company into a global leader in the development and commercialization of medicines for rare diseases. Mr. Lapointe also serves on the boards of directors of Soligenix, Inc., and Astria Therapeutics, Inc. He previously sat on the board of SciClone Pharmaceuticals, Inc., ImmunoCellular Therapeutics, Inc., Raptor Pharmaceuticals, Inc., Questcor Pharmaceuticals, Inc. and Cambrooke Therapeutics, Inc., among others. From 2009 to 2012, Mr. Lapointe was a member of the board of directors, and chair of the rare disease committee, of the Pharmaceutical Research and Manufacturers of America (PhRMA) in Washington, DC. He holds a Bachelor of Commerce degree from Concordia University (Montreal), a Graduate Diploma in Public Accountancy from McGill University (Montreal), an MBA from Duke University, and is a CPA (Illinois).
The Board concluded that Mr. Lapointe should continue to serve as a member of the Board in part due to his significant experience in the areas of global strategic planning and implementation, business development, corporate finance, and acquisitions, and his experience as an executive officer and board member in the pharmaceutical and medical products industries.
Brian L. Kotzin, M.D., age 73, joined us as a director in August 2017. A board-certified rheumatologist and internist, Dr. Kotzin is currently senior vice president and head of immunology at Nektar Therapeutics. He has been senior vice president, clinical development since April 2017 and has served as interim chief medical officer and head, clinical development Dr. Kotzin also serves on the board of directors of Progenity, Inc. From 2004 to 2015, he was vice president, global and clinical development and head, inflammation therapeutic area at Amgen Inc. (“Amgen”), directing the global development efforts for product candidates in the inflammation area. Before